Glibenclamide partly reverses monesin inhibition of insulin secretion, in vivo.
Glibenclamide, a second generation sulfonylurea, is an oral hypoglycemic drug. It seems to act mainly on the ATP-driven K(+)- channels of the beta-cells of pancreas determining insulin secretion. Because monensin, a Na+/H+ antiport, is able when administered to rats in vivo to inhibit insulin secretion, the action of glibenclamide is studied on glycemia and insulinemia to verify if it can antagonize the action of monensin. The results show that glibenclamide is able to partly reverse ionophore induced hyperglycemia and the inhibition of insulin secretion. These results might be interpreted as if glibenclamide only reverses the ATP-driven K(+)- channel dependent insulin secretion. Moreover the antagonist action of glibenclamide is slightly delayed when both drugs are administered together. The role of Na+/H+ antiport in basal insulin secretion is discussed.
Casu
A
A
Institute of General Pathology, University of Genoa, Italy.
Camogliano
L
L
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects; D005260:Female; D005905:Glyburide / Q000494:pharmacology*; D006943:Hyperglycemia / Q000139:chemically induced; D007328:Insulin / Q000097:blood / Q000378:metabolism*; D000078790:Insulin Secretion; D008985:Monensin / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley
D001786:Blood Glucose; D007328:Insulin; D008985:Monensin; D005905:Glyburide